Concepedia

Debra M. Meyer

DM

13

Publications

1.6K

Citations

12

H-Index

1993

Active since

Affiliations

Pfizer (United States)(Current)

Monsanto (United States)

Washington University in St. Louis

Debra M. Meyer is an author at Pfizer (United States) specializing in medicine, pharmacology, and immunology.

Top concepts

Publications per year

1993–2021

13

Publications

13

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

Kamran Ghoreschi, Michael I. Jesson, Li Xiong et al. · The Journal of Immunology · 2011 · 628 citations · Full text

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

Debra M. Meyer, Michael I. Jesson, Xiong Li et al. · Journal of Inflammation · 2010 · 455 citations · Full text

JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production

Timothy P. LaBranche, Michael I. Jesson, Chad Storer et al. · Arthritis & Rheumatism · 2012 · 130 citations

Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis

Martin E. Dowty, Michael I. Jesson, Sarbani Ghosh et al. · Journal of Pharmacology and Experimental Therapeutics · 2013 · 116 citations

Th17 cells can provide B cell help in autoantibody induced arthritis

Cynthia L. Hickman‐Brecks, Jennifer Racz, Debra M. Meyer et al. · Journal of Autoimmunity · 2010 · 69 citations · Full text

, , +13

Rows per page

1–5 of 13